Fresh Tracks Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

Provided By Globe Newswire

Last update: May 10, 2023

Reported positive topline results from SAD and MAD parts of Phase 1 study of lead DYRK1A inhibitor FRTX-02 in March 2023

Ongoing evaluation of strategic options to further develop FRTX-02 and maximize shareholder value